



Spinal Cord Injuries Treatment

by [John Demas](#) on 04/06/10 at 3:04 pm

According to the last publication of Ranjan Gupta, MD, chair of the department of orthopaedic surgery and professor of orthopaedic surgery, anatomy and neurobiology, and biomedical engineering at the University of California, Irvine, that we can read in the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), newer therapeutic approaches including stem cell therapy as well as novel drug formulations, bring special promise for treatment of [Spinal Cord Injury patients](#).

“Yet, spinal cord injuries are especially difficult to treat because they involve more than a direct injury to the spine,” noted Dr. Gupta. “The primary mode of an SCI involves changes to the patient’s anatomy that occur as the result of the actual traumatic event. Secondary injuries may occur as a result of how the body responds to the primary injury, usually by producing scar tissue that can make treatment problematic.”

In addition Dr. Gupta points out that the area of these secondary injuries leads to many promising areas of study, from optimizing the acute treatment of the patient to pharmacologic interventions to cellular transplantation.

“Yet, to maximize the chances for recovery after SCI, early surgical intervention is essential,” he stated.

With the sustained, robust attention from scientists and clinicians, as well as the continued active support from the National Institutes of Health, there should be substantial changes in the clinical management of SCI over the next decade. “As long as the field is being actively researched, there is cause for renewed and continued hope”.

Dr. Gupta continues “patients with spinal cord injuries face possible significant neurologic problems, resulting in paralysis and other disabilities. Innovative treatment strategies such as stem cell transplantation have enjoyed renewed interest under the current administration,”

“Currently, the FDA has been more receptive to cellular transplantation trials, with one of the first trials being actively planned in the next two years,” he says. “While there have been several animal studies showing benefits from various pharmacological interventions, the human clinical trials are still pending.”

“It is extremely unlikely that SCI will respond to one single intervention, or that there will be a ‘magic bullet,’” he summarized. “Rather, the treatment of SCI will undoubtedly require a multidisciplinary approach and management.”

Demas & Rosenthal remains one of Sacramento’s most highly respected and accomplished personal injury law firms. We’ve been successfully representing clients since our firm first opened its doors back in 1993. Every Demas & Rosenthal attorney takes pride in obtaining the full compensation and complete justice owed to every client.